Overexpression of DOC-1R inhibits cell cycle G1/S transition by repressing CDK2 expression and activation

International Journal of Biological Sciences

Volumn 9, Issue 6, 2013, Pages 541-549

  Liu, Qi ^a   Liu, Xing ^a   Gao, Jinlan ^a   Shi, Xiuyan ^a   Hu, Xihua ^a   Wang, Shusen ^a   Luo, Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CDK2; CKI; Cyclin A; Cyclin E; DOC 1R; G1 S transition

Indexed keywords

CDK2 PROTEIN, HUMAN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DOC 1R PROTEIN, HUMAN; DOC-1R PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CDK2; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CKI.; DOC-1R; DRUG ANTAGONISM; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; HUMAN; METABOLISM; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

CDK2; CKI.; CYCLIN A; CYCLIN E; DOC-1R; G1/S TRANSITION;

CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; ENZYME ACTIVATION; G1 PHASE; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; ONCOGENE PROTEINS; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S PHASE; TRANSCRIPTION, GENETIC;

EID: 84879321873     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5763     Document Type: Article

References (32)

1. Zhang X, Tsao H, Tsuji T, et al. Identification and mutation analysis of DOC-1R, a DOC-1 growth suppressor-related gene. Biochem Biophys Res Commun. 1999;225:59-63.
2. Sheng XJ, Jiang L, Zhou WQ, et al. Cloning of the mouse Doc-1R gene by genomic walking. Zhong Hua Yi Xue Yi Chuan Xue Za Zhi. 2002;21:240-4.
3. Terret ME, Lefebvre C, Djiane A, et al. DOC-1R: A MAP kinase substrate that control microtubule organization of metaphase II mouse oocytes. Development. 2003;132:5169-77.
4. Zhou WQ, Jiang L, Sheng XJ, et al. Construction and expression of mouse DOC-1R antisense gene vector. Ai Zheng. 2002;21:122-6.
5. Li Z, Pützer BM. Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/CDK2 and G2/M checkpoint proteins. J Cell Mol Med. 2008;12:2427-38.
6. Wright RH, Castellano G, Bonet J, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev. 2012;26:1972-83.
7. Huang X, Summers MK, Pham V, et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell. 2011;42:511-23.
8. Neganova I, Vilella F, Atkinson SP, et al. An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells. 2011;29:651-9.
9. Baydoun HH, Pancewicz J, Bai X, et al. HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression. Mol Cancer. 2010;9:302.
10. De Boer L, Oakes V, Beamish H, et al. Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene. 2008;27:4261-8.
11. Chung JH, Bunz F. Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genet. 2010;6:e1000863.
12. Liu Q, Gao JL, Liu X, et al. Monitoring cyclin-dependent kinase 2 (CDK2) activity with Kinase-Glo, a luminescence-based ATP quantitative reagent. Afr J Biotechnol. 2011;10:1217-20.
13. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARγ. Mol Biol Cell. 2009;20:801-8.
14. Ovejero S, Ayala P, Bueno A, et al. Human Cdc14A regulates Wee1 stability by counteracting CDK-mediated phosphorylation. Mol Biol Cell. 2012;23:4515-25.
15. Tu YS, Kang XL, Zhou JG, et al. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol. 2011;670:356-64.
16. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex. Nature. 2010;376:313-20.
17. Prince T, Sun L, Matts RL. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemisty. 2005;44:15287-95.
18. Futreal A, Otyepka M, Mann DJ. A cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase 2 alters the stability of cyclin binding. Biochim Biophys Acta. 2010;803:858-64.
19. Garcia HH, Brar GA, Nguyen DH, et al. Indole-3-Carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem. 2005;280:8756-64.
20. Campaner S, Doni M, Hydbring P, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene Myc and a Cdk2 senescence switch. Nat Cell Biol. 2010;12:54-9.
21. Viera A, Rufas JS, Martínez I, et al. CDK2 is required for proper homologous pairing, recombination and sex-body formation during male mouse meiosis. J Cell Sci. 2009;122:2149-59.
22. Hwang CY, Lee SM, Park SS, et al. CDK2 differentially controls normal cell senescence and cancer cell proliferation upon exposure to reactive oxygen species. Biochem Biophys Res Commun. 2012;425:94-9.
23. Hiromura K, Pippin JW, Blonski MJ, et al. The subcellular localization of cyclin-dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation. Oncogene. 2002;21:1750-8.
24. Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci. 2011;7:1122-44.
25. Fang Y, DeMarco VG, Nicholl MB. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci. 2012;103:1090-8.
26. DOC-1 is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol. 2000;21:6300-7.
27. DOC-1R. Biochem Biophys Res Commun. 2004;315:998-1003.
28. Waf1: contemporary view on its role in senescence and oncogenesis. Biochemistry. 2012;77:575-84.
29. Chiariello M, Gomez E, Gutkind S. Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G1 phase. Biochem J. 2000;349:869-76.
30. Blanchard DA, Mouhamad S, Auffredou MT, et al. Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP kinase activation in IL-2-dependent Kit 225 T lymphocytes. Oncogene. 2000;19:4184-9.
31. Berthet C, Aleem E, Coppola V, et al. Cdk2 knockout mice are viable. Curr Biol. 2003;13:1775-85.
32. Hanse EA, Nelsen CJ, Goggin MM, et al. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle. 2009; 8:2802-9.